Royal Bank of Canada
IKT icon

Royal Bank of Canada’s Inhibikase Therapeutics IKT Stock Holding History

Royal Bank of Canada’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3K Sell
1,614
-5,039
-76% -$8.95K ﹤0.01% 6591
2025
Q4 		$14K Buy
6,653
+5,990
+903% +$9.53K ﹤0.01% 6234
2025
Q3 		$1K Sell
663
-3,924
-86% -$6.8K ﹤0.01% 6992
2025
Q2 		$10K Buy
+4,587
New +$8.98K ﹤0.01% 6478
2024
Q1 		– Sell
-2,000
Closed -$3K – 7261
2023
Q4 		$3K Buy
+2,000
New +$2.07K ﹤0.01% 6731
2021
Q2 		– Sell
-333
Closed -$12K – 7569
2021
Q1 		$12K Sell
333
-500
-60% -$20.2K ﹤0.01% 6714
2020
Q4 		$35K Buy
+833
New +$42.2K ﹤0.01% 5806

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Royal Bank of Canada's IKT Position: Q1 2026 in Review

Royal Bank of Canada reduced its Inhibikase Therapeutics (IKT) stake by 76% in Q1 2026, selling an estimated $8.95K and leaving 1,614 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #6591.

Royal Bank of Canada first reported a position in IKT in Q4 2020 and has held it in 7 quarters since. The position peaked at $35K in Q4 2020. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Royal Bank of Canada held 1,614 shares of Inhibikase Therapeutics worth $3K as of Q1 2026.
  • Royal Bank of Canada sold 5,039 Inhibikase Therapeutics shares in Q1 2026, an estimated $8.95K.
  • Inhibikase Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6591 holding.
  • Royal Bank of Canada first reported a position in Inhibikase Therapeutics in Q4 2020 and has held it in 7 quarters since.
  • Royal Bank of Canada's Inhibikase Therapeutics position peaked at $35K in Q4 2020.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.